Compounds > acetylcarnitine
Page last updated: 2024-10-15

acetylcarnitine and Peripheral Nervous System Diseases

acetylcarnitine has been researched along with Peripheral Nervous System Diseases in 44 studies

Acetylcarnitine: An acetic acid ester of CARNITINE that facilitates movement of ACETYL COA into the matrices of mammalian MITOCHONDRIA during the oxidation of FATTY ACIDS.

Peripheral Nervous System Diseases: Diseases of the peripheral nerves external to the brain and spinal cord, which includes diseases of the nerve roots, ganglia, plexi, autonomic nerves, sensory nerves, and motor nerves.

Research Excerpts

ExcerptRelevanceReference
"Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)."9.19Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014)
"Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel."7.74Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008)
"This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain."7.73Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006)
"Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)."6.79Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014)
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons."5.38Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012)
"Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)."5.19Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014)
"Prophylactic treatment with acetyl-L-carnitine (ALCAR) prevents the neuropathic pain syndrome that is evoked by the chemotherapeutic agent, paclitaxel."3.74Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells. ( Bennett, GJ; Flatters, SJ; Jin, HW; Mulhern, HL; Xiao, WH, 2008)
"This study examines the potential efficacy of acetyl-L-carnitine (ALC) to prevent and treat paclitaxel-induced pain."3.73Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy. ( Bennett, GJ; Flatters, SJ; Xiao, WH, 2006)
"Retreatment with bortezomib (B) is often considered for patients with relapsed multiple myeloma (MM), but this strategy is hindered by uncertainty of response and emergence of B-induced peripheral neuropathy (PN)."2.79Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo ( Asimakopoulos, F; Callander, N; Campbell, T; Eickhoff, J; Go, R; Hegeman, R; Hematti, P; Hutson, P; Longo, W; Markovina, S; Miyamoto, S; Williams, E, 2014)
"Peripheral neuropathy (PN) is a recognized side effect of microtubule-targeting agents and the most clinically relevant toxicity observed with the epothilone sagopilone (SAG)."2.78A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013)
"Methods."2.78A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy. ( Baurain, JF; Berton-Rigaud, D; Campone, M; de Bont, N; Fabbro, M; Joly-Lobbedez, F; Pautier, P; Pinkert, J; Rolland, F; Schmelter, T; Stenzl, A; van Dijk, M, 2013)
"Treatment of peripheral neuropathies is targeted to its symptomatic and aetiological features."2.44Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007)
"Peripheral neuropathies are extremely heterogeneous nosological entities."2.44Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies. ( Capiluppi, E; Mailland, E; Mariani, C; Nascimbene, C; Osio, M; Vanotti, A, 2007)
"CIPN is an important consequence of cancer treatment because of its potential impact on physical functioning and quality of life."2.44Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy. ( Abbott, L; Aschenbrenner, J; Collins, M; Hart, C; Visovsky, C, 2007)
" Evidence from animal models of chemotherapy-induced painful peripheral neuropathy produced by the taxane agent, paclitaxel, and the platinum-complex agent, oxaliplatin, indicate that they produce neuropathy via a common mechanism-a toxic effect on the mitochondria in primary afferent sensory neurons."1.38Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy. ( Bennett, GJ; Xiao, WH; Zheng, H, 2012)
"OVCAR-3 and SKOV-3 ovarian cancer lines were incubated in ALCAR containing media."1.35Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin. ( Belisle, JA; Engle, DB; Gubbels, JA; Hutson, PR; Kushner, DM; Patankar, MS; Petrie, SE, 2009)
"Peripheral neuropathies are widespread disorders induced by autoimmune diseases, drug or toxin exposure, infections, metabolic insults or trauma."1.34Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy. ( Bartolini, A; Calvani, M; Di Cesare Mannelli, L; Ghelardini, C; Mosconi, L; Nicolai, R; Pacini, A; Vivoli, E, 2007)

Research

Studies (44)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's9 (20.45)18.2507
2000's19 (43.18)29.6817
2010's15 (34.09)24.3611
2020's1 (2.27)2.80

Authors

AuthorsStudies
Parisi, S1
Ditto, MC1
Borrelli, R1
Fusaro, E1
Dinicola, S1
Fuso, A1
Cucina, A1
Santiago-Reyes, M1
Verna, R1
Unfer, V1
Monastra, G1
Bizzarri, M1
Rowin, J1
Schloss, JM1
Colosimo, M1
Airey, C1
Masci, PP1
Linnane, AW1
Vitetta, L1
Hershman, DL1
Unger, JM1
Crew, KD1
Minasian, LM1
Awad, D1
Moinpour, CM1
Hansen, L1
Lew, DL1
Greenlee, H1
Fehrenbacher, L1
Wade, JL1
Wong, SF1
Hortobagyi, GN1
Meyskens, FL1
Albain, KS1
Hutchinson, L1
Onofrj, M2
Ciccocioppo, F1
Varanese, S1
di Muzio, A1
Calvani, M3
Chiechio, S3
Osio, M3
Thomas, A1
Campone, M1
Berton-Rigaud, D1
Joly-Lobbedez, F1
Baurain, JF1
Rolland, F1
Stenzl, A1
Fabbro, M1
van Dijk, M1
Pinkert, J1
Schmelter, T1
de Bont, N1
Pautier, P1
Burotto, M1
Fojo, AT1
Callander, N1
Markovina, S1
Eickhoff, J1
Hutson, P1
Campbell, T1
Hematti, P1
Go, R1
Hegeman, R1
Longo, W1
Williams, E1
Asimakopoulos, F1
Miyamoto, S1
Onysko, M1
Legerski, P1
Potthoff, J1
Erlandson, M1
Traina, G1
van Dam, DG1
Beijers, AJ1
Vreugdenhil, G1
Wolf, S1
Barton, D1
Kottschade, L1
Grothey, A1
Loprinzi, C1
Valcour, V1
Yeh, TM1
Bartt, R1
Clifford, D1
Gerschenson, M1
Evans, SR1
Cohen, BA1
Ebenezer, GJ1
Hauer, P1
Millar, L1
Gould, M1
Tran, P1
Shikuma, C1
Souza, S1
McArthur, JC1
Engle, DB1
Belisle, JA1
Gubbels, JA1
Petrie, SE1
Hutson, PR1
Kushner, DM1
Patankar, MS1
Vivoli, E2
Di Cesare Mannelli, L2
Salvicchi, A1
Bartolini, A2
Koverech, A1
Nicolai, R3
Benatti, P1
Ghelardini, C2
Binienda, ZK1
Beaudoin, MA1
Gough, B1
Ali, SF1
Virmani, A1
Zheng, H1
Xiao, WH4
Bennett, GJ4
Hart, AM1
Wilson, AD1
Montovani, C1
Smith, C1
Johnson, M1
Terenghi, G1
Youle, M2
Copani, A2
Melchiorri, D1
Canudas, AM1
Storto, M1
Nicoletti, F2
Flatters, SJ2
Muscia, F1
Zampini, L1
Nascimbene, C2
Mailland, E2
Cargnel, A1
Mariani, C2
Vanotti, A1
Capiluppi, E1
Gereau, RW1
De Grandis, D1
Mosconi, L1
Pacini, A1
Visovsky, C1
Collins, M1
Abbott, L1
Aschenbrenner, J1
Hart, C1
Jin, HW1
Mulhern, HL1
Fulgente, T1
Melchionda, D1
Marchionni, A1
Tomasello, F1
Salpietro, FM1
Alafaci, C1
De Sanctis, E1
Pennisi, G1
Bella, R1
Famularo, G2
Moretti, S1
Marcellini, S1
Trinchieri, V1
Tzantzoglou, S1
Santini, G1
Longo, A1
De Simone, C2
Scarpini, E1
Sacilotto, G1
Baron, P1
Cusini, M1
Scarlato, G1
James, JS1
Tenconi, B1
Donadoni, L1
Germani, E1
Bertelli, A1
Mantegazza, P1
Di Giulio, AM1
Ramacci, MT2
Gorio, A1
De Angelis, C1
Scarfò, C1
Falcinelli, M1
Reda, E1
Angelucci, L1

Clinical Trials (9)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Preventive Effect of Acetyl-L-carnitine on Oxaliplatin-induced Peripheral Neuropathy： A Randomized, Controlled, Open-label, Phase 2 Trail[NCT05601479]Phase 2100 participants (Anticipated)Interventional2022-11-01Not yet recruiting
S0715: Randomized Placebo-Controlled Trial of Acetyl-L-Carnitine (ALC) for the Prevention of Taxane Induced Neuropathy Phase III[NCT00775645]Phase 3437 participants (Actual)Interventional2009-09-30Completed
Multi-Center, Randomized, Double-Blind Active-Controlled, Parallel Group Study to Investigate Plasma Folate, Red Blood Cell Folate and Homocysteine Levels During a 24 Week Oral Administration of an OC Containing Folate Compared to OC Alone[NCT00468481]Phase 3385 participants (Actual)Interventional2007-04-30Completed
(REASON) Double-blind, Randomized Phase II Study to Evaluate the Safety and Efficacy of Acetyl-l-carnitine in the Prevention of Sagopilone-induced Peripheral Neuropathy.[NCT00751205]Phase 2150 participants (Actual)Interventional2008-08-31Completed
Diode Laser as a Biomarker for Neuropathic Pain of Peripheral Origin.[NCT06030297]301 participants (Anticipated)Interventional2022-11-01Recruiting
Prevalence of Paclitaxel Induced CIPN-Related Pain and CIPN in Indian Patients With Breast Cancer : A Prospective Observational Study[NCT03022162]150 participants (Actual)Observational2017-12-01Completed
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study of Duloxetine and Methadone for the Treatment of HIV-Associated Painful Peripheral Neuropathy[NCT00863057]Phase 215 participants (Actual)Interventional2009-05-31Terminated (stopped due to Due to slow rate of enrollment, which compromised the ability to meet study objectives in a timely manner.)
Early Detection of Taxane-Induced Neuropathy in Women With Breast Cancer[NCT02549534]29 participants (Actual)Observational2015-09-30Completed
An Open-Label, Dose-Escalation Pilot Study of Acetyl-L-Carnitine for the Treatment of Dideoxynucleoside-Associated Distal Symmetric Peripheral Neuropathy[NCT00050271]27 participants (Actual)InterventionalCompleted
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

12-week FACIT-fatigue Model-adjusted Score in ALC and Placebo Groups

Compare fatigue outcome between treatment and placebo groups as measured by the 13-item Functional Assessment of Chronic Illness Therapy FACIT-fatigue questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate more fatigue. Total possible range is 0 to 52. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

InterventionFACIT-fatigue score (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))36.6
Arm II (Placebo)35.3

12-week FACT-Taxane Neurotoxicity Model-adjusted Score in ALC and Placebo Groups

Compare whether treatment with acetyl-L-carnitine hydrochloride vs placebo prevents symptoms of neuropathy as measured by the 11-item neurotoxicity (NTX) component of the Functional Assesment of Cancer Therapy (FACT)-Taxane Questionnaire at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse CIPN. Total possible range is 0 to 64. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

Interventionunits on a scale (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))35.4
Arm II (Placebo)36.3

12-week FACT-Trial Outcome Index(TOI) Functional Status Model-adjusted Score in ALC and Placebo Groups

Compare FACT-TOI outcome in treatment vs placebo groups at 12 weeks after study registration in women with breast cancer undergoing adjuvant taxane-based chemotherapy. Linear regression model adjusted for baseline score, taxane regiment, and age. Lower scores indicate worse functional status. Total possible range is 0 to 120. For more information on this subscale, please see http://www.facit.org/FACITOrg/Questionnaires (NCT00775645)
Timeframe: 12 weeks post-registration

Interventionunits on a scale (Mean)
Arm I (Acetyl-L-carnitine Hydrochloride))92.1
Arm II (Placebo)92.3

Proportion of Patients Experiencing Grade 3 or 4 Neuropathy

Proportion of patients experiencing grade 3 or 4 neuropathy (NCT00775645)
Timeframe: 12 weeks post-registration

InterventionParticipants (Count of Participants)
Arm I (Acetyl-L-carnitine Hydrochloride))8
Arm II (Placebo)1

Mean Change From Baseline in Plasma Folate Levels at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)0.3

Mean Change From Baseline in Plasma Folate Levels at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)17.6
Drospirenone (DRSP)/Ethinylestradiol (EE)2.4

Mean Change From Baseline in Plasma Folate Levels at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.1
Drospirenone (DRSP)/Ethinylestradiol (EE)-1.6

Mean Change From Baseline in Plasma Folate Levels at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)15.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0.6

Mean Change From Baseline in Plasma Folate Levels at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)18.4
Drospirenone (DRSP)/Ethinylestradiol (EE)2.2

Mean Change From Baseline in Plasma Homocysteine Levels at Week 12

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 12

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0

Mean Change From Baseline in Plasma Homocysteine Levels at Week 16

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 16

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.1

Mean Change From Baseline in Plasma Homocysteine Levels at Week 20

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 20

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.2

Mean Change From Baseline in Plasma Homocysteine Levels at Week 24

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 24

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.3
Drospirenone (DRSP)/Ethinylestradiol (EE)0.1

Mean Change From Baseline in Plasma Homocysteine Levels at Week 4

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 4

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)0
Drospirenone (DRSP)/Ethinylestradiol (EE)0

Mean Change From Baseline in Plasma Homocysteine Levels at Week 8

Homocysteine concentrations in plasma were determined by Fluorescence Polarization Immunoassays (FPIA) using the Abbot AxSym analyzer in a clinical laboratory setting. (NCT00468481)
Timeframe: baseline and up to week 8

Interventionµg/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.2
Drospirenone (DRSP)/Ethinylestradiol (EE)0

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)405.8
Drospirenone (DRSP)/Ethinylestradiol (EE)86.5

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)448.9
Drospirenone (DRSP)/Ethinylestradiol (EE)68.0

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)452.7
Drospirenone (DRSP)/Ethinylestradiol (EE)64.6

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)110.9
Drospirenone (DRSP)/Ethinylestradiol (EE)-37.6

Mean Change From Baseline in Red Blood Cell (RBC) Folate Levels at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: baseline and up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)310.3
Drospirenone (DRSP)/Ethinylestradiol (EE)68.2

Mean Neural Tube Defect (NTD) Risk Reduction at Week 24

The mean NTD risk reduction evaluated as the change from Baseline to Week 24 in NTD risk based on the formula of Daly et al (J Amer Med Assoc 1995;274(21):1698-702); NTD risk=exp (1.6463-1.2193 x natural log [RBC folate]) where natural log [RBC folate] is the natural log of RBC folate measured in nmol/L; Change from Baseline to Week 24 in NTD risk=NTD risk at Week 24 - NTD risk at Baseline (NCT00468481)
Timeframe: Baseline and week 24

Interventionper 1000 birth (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)-0.51
Drospirenone (DRSP)/Ethinylestradiol (EE)-0.03

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)50.3
Drospirenone (DRSP)/Ethinylestradiol (EE)47.1

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.4
Drospirenone (DRSP)/Ethinylestradiol (EE)46.4

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)67.5
Drospirenone (DRSP)/Ethinylestradiol (EE)51.8

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)61.5
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)64.0
Drospirenone (DRSP)/Ethinylestradiol (EE)43.7

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.4
Drospirenone (DRSP)/Ethinylestradiol (EE)45.9

Mean Plasma Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)68.1
Drospirenone (DRSP)/Ethinylestradiol (EE)54.1

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)41.7
Drospirenone (DRSP)/Ethinylestradiol (EE)41.5

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.5
Drospirenone (DRSP)/Ethinylestradiol (EE)42.3

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.4
Drospirenone (DRSP)/Ethinylestradiol (EE)43.2

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.8
Drospirenone (DRSP)/Ethinylestradiol (EE)39.7

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)58.7
Drospirenone (DRSP)/Ethinylestradiol (EE)39.8

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)59.6
Drospirenone (DRSP)/Ethinylestradiol (EE)43.1

Mean Plasma Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.8
Drospirenone (DRSP)/Ethinylestradiol (EE)41.8

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1122.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1345.0

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1469.8
Drospirenone (DRSP)/Ethinylestradiol (EE)1378.4

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1460.5
Drospirenone (DRSP)/Ethinylestradiol (EE)1454.7

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1486.6
Drospirenone (DRSP)/Ethinylestradiol (EE)1435.9

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1500.3
Drospirenone (DRSP)/Ethinylestradiol (EE)1316.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1175.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1256.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (With Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1412.7
Drospirenone (DRSP)/Ethinylestradiol (EE)1407.6

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Baseline

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: at baseline (week 0)

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)910.9
Drospirenone (DRSP)/Ethinylestradiol (EE)915.1

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 12

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 12

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1308.9
Drospirenone (DRSP)/Ethinylestradiol (EE)1025.2

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 16

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 16

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1365.2
Drospirenone (DRSP)/Ethinylestradiol (EE)967.6

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 20

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 20

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1419.8
Drospirenone (DRSP)/Ethinylestradiol (EE)981.3

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 24

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 24

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1355.3
Drospirenone (DRSP)/Ethinylestradiol (EE)949.2

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 4

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 4

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1007.1
Drospirenone (DRSP)/Ethinylestradiol (EE)889.5

Mean Red Blood Cell (RBC) Folate Levels by Additional Folate Supplementation (Without Additional Folate Supplementation) at Week 8

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: up to week 8

Interventionnmol/L (Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1184.8
Drospirenone (DRSP)/Ethinylestradiol (EE)970.4

Plasma Folate Level at 24 Weeks

Folate concentrations in plasma were determined by an appropriately validated microbiological assay. (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)60.55
Drospirenone (DRSP)/Ethinylestradiol (EE)41.67

Red Blood Cell (RBC) Folate Level at 24 Weeks

RBC folate=([whole blood folate*100]-[plasma folate*(100-hematocrit)])/hematocrit (NCT00468481)
Timeframe: Week 24

Interventionnmol/L (Least Squares Mean)
Drospirenone (DRSP)/Ethinylestradiol (EE)/Metafolin (MTHF)1406.91
Drospirenone (DRSP)/Ethinylestradiol (EE)1022.21

Emotional Functioning as Measured by the Center for Epidemiologic Studies Depression Scale (CES-D)

The CES-D is a 20-item self-report rating inventory measuring characteristic attitudes and symptoms of depression. Participants were asked to score each item: (0) Rarely, (1) Occasionally, (2) Sometimes, and (3) Most of time. Some items are multiplied by -1 to change direction. The overall CES-D score is simply the sum of 20 items. The highest possible total CES-D score is 48, and the lowest possible score is -12. The total CES-D score is considered missing if more than 4 items are not answered. (NCT00863057)
Timeframe: At the fourth treatment week of each treatment period

InterventionScores on a scale (Mean)
Duloxetine and Methadone13.8
Duloxetine and Methadone Placebo13.8
Duloxetine Placebo and Methadone13.3
Duloxetine Placebo and Methadone Placebo13.3

Maximum Tolerated Dose of Duloxetine and Methadone

(NCT00863057)
Timeframe: During each treatment period

Interventionmg (Number)
Methadone30
Duloxetine60

Mean Nighttime Pain Measure on an 11-point Likert Scale

"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine.~Participants were given pain diaries at weeks 0, 5, 10, and 15. They started the diary 7 days prior to their clinic visits at weeks 0, 4, 9, 14, and 19. During the 7 days, each morning, they recorded their pain level due to neuropathy by circling the number that best described their neuropathy pain on average during the night time." (NCT00863057)
Timeframe: Over the fourth treatment week of each treatment period

InterventionScores on a scale (Mean)
Duloxetine and Methadone5.20
Duloxetine and Methadone Placebo5.82
Duloxetine Placebo and Methadone5.90
Duloxetine Placebo and Methadone Placebo6.10

Number of Participants With 30% or More Improvement in Mean Pain Score on an 11-point Likert Scale

"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine at baseline and over the fourth treatment week of each treatment period.~The % of improvement was calculated as (x-y)/x,where x was the MPI score at baseline, and y was the MPI score at the end of each treatment stage." (NCT00863057)
Timeframe: At Baseline and over the fourth treatment week of each treatment period

Interventionparticipants (Number)
Duloxetine and Methadone2
Duloxetine and Methadone Placebo2
Duloxetine Placebo and Methadone2
Duloxetine Placebo and Methadone Placebo2

Number of Participants With 50% or More Improvement in Mean Pain Score on an 11-point Likert Scale

"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine at baseline and over the fourth treatment week of each treatment period.~The % of improvement was calculated as (x-y)/x,where x was the MPI score at baseline, and y was the MPI score at the end of each treatment stage." (NCT00863057)
Timeframe: At Baseline and over the fourth treatment week of each treatment period

Interventionparticipants (Number)
Duloxetine and Methadone2
Duloxetine and Methadone Placebo2
Duloxetine Placebo and Methadone1
Duloxetine Placebo and Methadone Placebo2

Number of Participants With Treatment-emergent Grade 2 to 4 Adverse Events

The DAIDS Table for Grading the Severity of Adult and Pediatric Adverse Events (DAIDS AE Grading Table), Version 1.0, December 2004 was used (see the link to the grading table in Protocol Section) (NCT00863057)
Timeframe: From study entry to end of study at week 20 or premature study discontinuation

InterventionParticipants (Count of Participants)
Duloxetine and Methadone5
Duloxetine and Methadone Placebo4
Duloxetine Placebo and Methadone6
Duloxetine Placebo and Methadone Placebo5

Pain-related Interference Measured by the Brief Pain Inventory (BPI) Interference Items

"The BPI interference scale measured level of interference with the following seven items:~General activity~Mood~Walking ability~Normal work~Relations with other people~Sleep~Enjoyment of life~Interference scales range from 0='Does not interfere' to 10='Completely interferes'. The overall BPI score is the mean of seven item with the minimum and maximal scores of 0 and 70, respectively." (NCT00863057)
Timeframe: At the fourth week of each treatment period

InterventionScores on a scale (Median)
Duloxetine and Methadone3.14
Duloxetine and Methadone Placebo4.14
Duloxetine Placebo and Methadone3.64
Duloxetine Placebo and Methadone Placebo3.14

Weekly Mean Pain Score Derived From Self-reported Average Daily Pain Intensity on an 11-point Likert Scale

"Pain was measured on an 11-point Likert numerical rating scale, ranging from 0=''No pain to 10=''Pain as bad as you can imagine.~Participants were given pain diaries at weeks 0, 5, 10, and 15. They started the diary 7 days prior to their clinic visits at weeks 0, 4, 9, 14, and 19. During the 7 days, each morning, they recorded their pain level due to neuropathy by circling the number that best described their neuropathy pain on average over the past 24 hours." (NCT00863057)
Timeframe: During the fourth treatment week of each treatment period

InterventionScores on a scale (Mean)
Duloxetine and Methadone5.20
Duloxetine and Methadone Placebo5.91
Duloxetine Placebo and Methadone6.20
Duloxetine Placebo and Methadone Placebo5.70

Patient and Clinician Global Impression of Change (PGIC and CGIC) on a 7-point Likert Scale

"The GIC scale is a validated instrument that consists of seven verbal descriptors on a 7-point scale:~Very much improved~Much improved~Minimally improved~No change~Minimally worse~Much worse~Very much worse~Participants were carefully instructed to consider the impact of study treatments on their level of neuropathic pain intensity during the baseline phase of the study." (NCT00863057)
Timeframe: At the fourth treatment week of each treatment period

,,,
Interventionparticipants (Number)
PGIC - Very much improvedPGIC - Much improvedPGIC - Minimally improvedPGIC - No changePGIC - Much worseCGIC - Very much improvedCGIC - Much improvedCGIC - Minimally improvedCGIC - No changeCGIC - Much worse
Duloxetine and Methadone1423014140
Duloxetine and Methadone Placebo0146011180
Duloxetine Placebo and Methadone1242113330
Duloxetine Placebo and Methadone Placebo1144011341

Use of Rescue Medication (Acetaminophen)

(NCT00863057)
Timeframe: During each treatment period and the subsequent cross-over (or final study week) period

,,,
Interventionparticipants (Number)
Treatment period (1-4, 6-9, 11-14, 16-19 weeks)Cross-over period (5, 10, 15, 20 weeks)
Duloxetine and Methadone01
Duloxetine and Methadone Placebo00
Duloxetine Placebo and Methadone01
Duloxetine Placebo and Methadone Placebo21

Reviews

13 reviews available for acetylcarnitine and Peripheral Nervous System Diseases

ArticleYear
Natural products - alpha-lipoic acid and acetyl-L-carnitine - in the treatment of chemotherapy-induced peripheral neuropathy.
    European review for medical and pharmacological sciences, 2018, Volume: 22, Issue:14

    Topics: Acetylcarnitine; Animals; Antineoplastic Agents; Biological Products; Humans; Peripheral Nervous Sys

2018
Integrative neuromuscular medicine: Neuropathy and neuropathic pain: Consider the alternatives.
    Muscle & nerve, 2019, Volume: 60, Issue:2

    Topics: Acetylcarnitine; Anti-Inflammatory Agents, Non-Steroidal; Curcumin; Diet; Diet Therapy; Dietary Supp

2019
Nutraceuticals and chemotherapy induced peripheral neuropathy (CIPN): a systematic review.
    Clinical nutrition (Edinburgh, Scotland), 2013, Volume: 32, Issue:6

    Topics: Acetylcarnitine; Acetylcysteine; Antineoplastic Agents; Dietary Supplements; Fatty Acids, Omega-3; G

2013
Acetyl-L-carnitine: from a biological curiosity to a drug for the peripheral nervous system and beyond.
    Expert review of neurotherapeutics, 2013, Volume: 13, Issue:8

    Topics: Acetylcarnitine; Animals; Humans; Neuralgia; Nootropic Agents; Peripheral Nervous System Diseases

2013
Targeting neuropathic pain: consider these alternatives.
    The Journal of family practice, 2015, Volume: 64, Issue:8

    Topics: Acetylcarnitine; Capsaicin; Complementary Therapies; Family Practice; gamma-Linolenic Acid; Humans;

2015
The neurobiology of acetyl-L-carnitine.
    Frontiers in bioscience (Landmark edition), 2016, 06-01, Volume: 21, Issue:7

    Topics: Acetylcarnitine; Aging; Animals; Apoptosis; Brain; Dietary Supplements; Energy Metabolism; Epigenesi

2016
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11

    Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A

2008
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11

    Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A

2008
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11

    Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A

2008
Chemotherapy-induced peripheral neuropathy: prevention and treatment strategies.
    European journal of cancer (Oxford, England : 1990), 2008, Volume: 44, Issue:11

    Topics: Acetylcarnitine; Acetylcysteine; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplastic A

2008
Metabotropic receptors as targets for drugs of potential use in the treatment of neuropathic pain.
    Journal of endocrinological investigation, 2004, Volume: 27, Issue:6 Suppl

    Topics: Acetylcarnitine; Analgesics; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Dise

2004
Overview on pathophysiology and newer approaches to treatment of peripheral neuropathies.
    CNS drugs, 2007, Volume: 21 Suppl 1

    Topics: Acetylcarnitine; Analgesics, Opioid; Animals; Anticonvulsants; Antidepressive Agents; Antineoplastic

2007
Acetyl-L-carnitine in HIV-associated antiretroviral toxic neuropathy.
    CNS drugs, 2007, Volume: 21 Suppl 1

    Topics: Acetylcarnitine; Animals; Antiretroviral Therapy, Highly Active; Clinical Trials as Topic; HIV Infec

2007
Acetyl-L-carnitine in neuropathic pain: experimental data.
    CNS drugs, 2007, Volume: 21 Suppl 1

    Topics: Acetylcarnitine; Analgesia; Animals; Humans; Nootropic Agents; Pain; Peripheral Nervous System Disea

2007
Acetyl-L-carnitine for the treatment of chemotherapy-induced peripheral neuropathy: a short review.
    CNS drugs, 2007, Volume: 21 Suppl 1

    Topics: Acetylcarnitine; Animals; Antineoplastic Agents; Clinical Trials as Topic; Humans; Nootropic Agents;

2007
Putting evidence into practice: evidence-based interventions for chemotherapy-induced peripheral neuropathy.
    Clinical journal of oncology nursing, 2007, Volume: 11, Issue:6

    Topics: Acetylcarnitine; Acupuncture Therapy; Anticonvulsants; Antidepressive Agents, Tricyclic; Antineoplas

2007

Trials

9 trials available for acetylcarnitine and Peripheral Nervous System Diseases

ArticleYear
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20

    Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re

2013
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20

    Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re

2013
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20

    Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re

2013
Randomized double-blind placebo-controlled trial of acetyl-L-carnitine for the prevention of taxane-induced neuropathy in women undergoing adjuvant breast cancer therapy.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2013, Jul-10, Volume: 31, Issue:20

    Topics: Acetylcarnitine; Adult; Aged; Breast Neoplasms; Chemotherapy, Adjuvant; Dietary Supplements; Dose-Re

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
A double-blind, randomized phase II study to evaluate the safety and efficacy of acetyl-L-carnitine in the prevention of sagopilone-induced peripheral neuropathy.
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Aged; Aged, 80 and over; Antineoplastic Agents; Benzothiazoles; Double-Blind

2013
Acetyl-L-carnitine (ALCAR) for the prevention of chemotherapy-induced peripheral neuropathy in patients with relapsed or refractory multiple myeloma treated with bortezomib, doxorubicin and low-dose dexamethasone: a study from the Wisconsin Oncology Netwo
    Cancer chemotherapy and pharmacology, 2014, Volume: 74, Issue:4

    Topics: Acetylcarnitine; Antineoplastic Agents; Boronic Acids; Bortezomib; Dexamethasone; Doxorubicin; Drug

2014
Acetyl-l-carnitine: a pathogenesis based treatment for HIV-associated antiretroviral toxic neuropathy.
    AIDS (London, England), 2004, Jul-23, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Adult; Cohort Studies; Female; HIV Infections; HIV Reverse Transcriptase; HIV-1; Hu

2004
Acetyl-l-carnitine in the treatment of painful antiretroviral toxic neuropathy in human immunodeficiency virus patients: an open label study.
    Journal of the peripheral nervous system : JPNS, 2006, Volume: 11, Issue:1

    Topics: Acetylcarnitine; Adult; Aged; Antiretroviral Therapy, Highly Active; HIV Infections; Humans; Middle

2006
Complications & side effects. Supplements and CD4+ counts: study finds surprising results.
    TreatmentUpdate, 2004, Volume: 16, Issue:2

    Topics: Acetylcarnitine; Acetylcysteine; Antioxidants; CD4 Lymphocyte Count; Dose-Response Relationship, Dru

2004
L-acetylcarnitine as a new therapeutic approach for peripheral neuropathies with pain.
    International journal of clinical pharmacology research, 1995, Volume: 15, Issue:1

    Topics: Acetylcarnitine; Adolescent; Adult; Aged; Double-Blind Method; Humans; Injections, Intramuscular; Mi

1995
Acetyl-carnitine deficiency in AIDS patients with neurotoxicity on treatment with antiretroviral nucleoside analogues.
    AIDS (London, England), 1997, Volume: 11, Issue:2

    Topics: Acetylcarnitine; Acquired Immunodeficiency Syndrome; Adult; Anti-HIV Agents; Axons; Cross-Sectional

1997
Effect of acetyl-L-carnitine in the treatment of painful peripheral neuropathies in HIV+ patients.
    Journal of the peripheral nervous system : JPNS, 1997, Volume: 2, Issue:3

    Topics: Acetylcarnitine; Adult; Female; HIV Seropositivity; Humans; Male; Middle Aged; Nootropic Agents; Pai

1997

Other Studies

22 other studies available for acetylcarnitine and Peripheral Nervous System Diseases

ArticleYear
Efficacy of a fixed combination of palmitoylethanolamide and acetyl-l-carnitine (PEA+ALC FC) in the treatment of neuropathies secondary to rheumatic diseases.
    Minerva medica, 2021, Volume: 112, Issue:4

    Topics: Acetylcarnitine; Aged; Amides; Analgesics, Non-Narcotic; Carpal Tunnel Syndrome; Drug Administration

2021
Chemotherapy: Supplements--for better or worse?
    Nature reviews. Clinical oncology, 2013, Volume: 10, Issue:8

    Topics: Acetylcarnitine; Breast Neoplasms; Female; Humans; Peripheral Nervous System Diseases; Taxoids

2013
Acetyl-L-carnitine and prevention of chemotherapy-induced peripheral neuropathy: can anything work?
    The oncologist, 2013, Volume: 18, Issue:11

    Topics: Acetylcarnitine; Benzothiazoles; Epothilones; Female; Humans; Male; Peripheral Nervous System Diseas

2013
Acetyl-L-carnitine undervalued in the treatment of chemotherapy-induced peripheral neuropathy?
    Acta oncologica (Stockholm, Sweden), 2016, Volume: 55, Issue:12

    Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; Humans; Neoplasms; Peripheral Nervo

2016
Acetyl-l-carnitine and nucleoside reverse transcriptase inhibitor-associated neuropathy in HIV infection.
    HIV medicine, 2009, Volume: 10, Issue:2

    Topics: Acetylcarnitine; AIDS-Related Opportunistic Infections; Confidence Intervals; DNA, Mitochondrial; Fe

2009
Effect of acetyl-l-carnitine on ovarian cancer cells' proliferation, nerve growth factor receptor (Trk-A and p75) expression, and the cytotoxic potential of paclitaxel and carboplatin.
    Gynecologic oncology, 2009, Volume: 112, Issue:3

    Topics: Acetylcarnitine; Antineoplastic Combined Chemotherapy Protocols; CA-125 Antigen; Carboplatin; Cell G

2009
Acetyl-L-carnitine increases artemin level and prevents neurotrophic factor alterations during neuropathy.
    Neuroscience, 2010, Jun-02, Volume: 167, Issue:4

    Topics: Acetylcarnitine; Analgesics; Animals; Constriction, Pathologic; Ganglia, Spinal; Male; Nerve Growth

2010
Assessment of 3-nitropropionic acid-evoked peripheral neuropathy in rats: neuroprotective effects of acetyl-l-carnitine and resveratrol.
    Neuroscience letters, 2010, Aug-16, Volume: 480, Issue:2

    Topics: Acetylcarnitine; Animals; Antioxidants; Axons; Environmental Pollutants; Male; Nerve Degeneration; N

2010
Mitotoxicity and bortezomib-induced chronic painful peripheral neuropathy.
    Experimental neurology, 2012, Volume: 238, Issue:2

    Topics: Acetylcarnitine; Activating Transcription Factor 3; Adenosine Triphosphate; Analysis of Variance; An

2012
Side effects. Helping to repair damaged nerves.
    TreatmentUpdate, 2000, Volume: 12, Issue:5

    Topics: Acetylcarnitine; Humans; Peripheral Nervous System Diseases; Reverse Transcriptase Inhibitors

2000
Acetyl-L-carnitine prevents and reduces paclitaxel-induced painful peripheral neuropathy.
    Neuroscience letters, 2006, Apr-24, Volume: 397, Issue:3

    Topics: Acetylcarnitine; Administration, Oral; Animals; Antineoplastic Agents, Phytogenic; Male; Paclitaxel;

2006
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
    Pain, 2008, Volume: 135, Issue:3

    Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E

2008
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
    Pain, 2008, Volume: 135, Issue:3

    Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E

2008
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
    Pain, 2008, Volume: 135, Issue:3

    Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E

2008
Chemotherapy-evoked neuropathic pain: Abnormal spontaneous discharge in A-fiber and C-fiber primary afferent neurons and its suppression by acetyl-L-carnitine.
    Pain, 2008, Volume: 135, Issue:3

    Topics: Acetylcarnitine; Action Potentials; Afferent Pathways; Analgesics; Animals; Antineoplastic Agents; E

2008
Protective effect of acetyl-L-carnitine on the apoptotic pathway of peripheral neuropathy.
    The European journal of neuroscience, 2007, Volume: 26, Issue:4

    Topics: Acetylcarnitine; Animals; Apoptosis; Blotting, Western; Caspase 3; Cytochromes c; Cytosol; DNA Fragm

2007
Prevention of paclitaxel-evoked painful peripheral neuropathy by acetyl-L-carnitine: effects on axonal mitochondria, sensory nerve fiber terminal arbors, and cutaneous Langerhans cells.
    Experimental neurology, 2008, Volume: 210, Issue:1

    Topics: Acetylcarnitine; Animals; Axons; Behavior, Animal; Disease Models, Animal; Drug Interactions; Langer

2008
Treatment with acetyl-L-carnitine has the potential to improve the clinical course of painful peripheral neuropathies in HIV-positives patients.
    Journal of the peripheral nervous system : JPNS, 1998, Volume: 3, Issue:3

    Topics: Acetylcarnitine; HIV Seropositivity; Humans; Peripheral Nervous System Diseases

1998
Amino acid may help neuropathy.
    AIDS patient care and STDs, 2000, Volume: 14, Issue:8

    Topics: Acetylcarnitine; Anti-HIV Agents; Biopsy; HIV Infections; Humans; Peripheral Nervous System Diseases

2000
Drug-related neuropathy: low acetylcarnitine levels found.
    AIDS treatment news, 1997, Feb-21, Issue:No 265

    Topics: Acetylcarnitine; Anti-HIV Agents; Humans; Nootropic Agents; Peripheral Nervous System Diseases

1997
What's L-A-C got to do with it?
    Notes from the underground (New York, N.Y.), 1997, Issue:No 36

    Topics: Acetylcarnitine; HIV Infections; Humans; Nootropic Agents; Peripheral Nervous System Diseases

1997
Acetylcarnitine and neuropathy: call for information.
    AIDS treatment news, 1998, Jun-05, Issue:No 296

    Topics: Acetylcarnitine; Clinical Trials as Topic; HIV Infections; Humans; Peripheral Nervous System Disease

1998
. . . from the 3rd International Workshop on salvage therapy for HIV infection.
    Research initiative, treatment action : RITA, 2000, Volume: 6, Issue:2

    Topics: Acetylcarnitine; HIV Infections; HIV Protease Inhibitors; Humans; Patient Compliance; Peripheral Ner

2000
Intraspinal degenerative atrophy caused by sciatic nerve lesions prevented by acetyl-L-carnitine.
    International journal of clinical pharmacology research, 1992, Volume: 12, Issue:5-6

    Topics: Acetylcarnitine; Animals; Atrophy; Enkephalin, Methionine; Hydroxyindoleacetic Acid; Male; Periphera

1992
Levocarnitine acetyl stimulates peripheral nerve regeneration and neuromuscular junction remodelling following sciatic nerve injury.
    International journal of clinical pharmacology research, 1992, Volume: 12, Issue:5-6

    Topics: Acetylcarnitine; Animals; Male; Nerve Crush; Nerve Degeneration; Nerve Regeneration; Neuromuscular J

1992